
compani
usd jan pm et
summari larg produc brand-nam prescript drug offer wide rang treatment
diabet neurolog disord cancer condit
price-to-earnings oper ep
risk assess reflect relentless effort
gener challeng brand-nam drug intens
competit brand drug maker treatment
market share brand-nam indic
uncertainti relat drug develop pipelin
regulatori approv also see risk increas
polit scrutini drug price risk
partial mitig robust develop pipelin
compani typic drug
phase ii later stage develop approv
pipelin drug like fuel long-term sale growth even
older drug declin
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan stock trade
year-to-d revenu thru modest
yoy rapid growth newer treatment
mostli off-set declin older
brand key contributor growth
diabet drug trulic
sale ytd growth yoy
diabet verzenio breast
cancer contribut sale growth
well
expect sale newer non-diabet
drug continu grow rapidli
none expect face gener competit
near term howev see potenti
trulic basaglar still grow
miss expect due intens competit
diabet market share rise polit
scrutini drug class
among older brand ytd sale
seller humalog diabet sale
fell yoy due biosimilar launch
yoy myriad gener
approv gain market share
think total sale growth improv
begin anniversari
exclus loss older blockbust drug
neutral share think
current valuat fairli reflect balanc
loss exclus legaci brand polit
scrutini price diabet drug roughli
revenu strong demand growth
newer brand expect trulic
basaglar diabet taltz psoriasi
verzenio breast cancer continu lead
way sale growth growth
rate
portfolio face current near-term
exclus loss sever blockbust drug
includ humalog alimta forteo ciali
think long-term pipelin
backfil declin novel drug
current regulatori review anoth
target price ep
estim forward price-to-earnings
averag due potenti polit price
pressur diabet drug drug
becom focal point politician view
due high preval diabet
nearli live condit
unexpect biosimilar launch pipelin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president financ
chief oper offic
compani
corpor overview compani fifth largest drug maker term revenu
lead develop drug wide rang therapeut area includ endocrinolog
incud diabet drug portfolio gener roughli half total revenu well cardiovascular
immunolog neurosci oncolog
drug portfolio drug portfolio concentr larger peer view
half revenu come top six drug compani top-sel drug includ trulic
diabet billion sale total humalog diabet billion sale
total alimta lung cancer billion sale total ciali erectil dysfunct
billion sale total forteo osteoporosi billion sale total
humulin diabet billion sale total
critic drug compani like consist success new drug growth mode order
off-set older drug declin sale due loss exclus competit new
improv treatment exampl type declin erectil dysfunct drug ciali whose
sale peak around billion declin patent expir convers
trulic diabet still earli exclus period expir achiev rapid sale
growth offset declin ciali sale
next five year face sever key exclus expir hope off-set growth
newer drug critic upcom patent expir end data exclus period includ forteo
sale alimta sale cymbalta sale given
larg expect sale impact alimta lung cancer upcom loss exclus
focus major acquisit dollar promis develop asset oncolog detail major
develop section
research develop effort continu off-set declin sale older drug spend
heavili research develop keep new drug come pipelin
global drug market spend total billion repres total revenu
februari drug develop pipelin consist on-going clinic trial
variou phase total trial phase final stage human clinic trial
registr phase fda approv final regulatori review drug market phase
later trial new molecular entiti nme often greater market potenti
new indic trial intend expand treatment indic already-approv drug get
approv lung cancer drug approv new breast cancer indic
develop pipelin includ potenti new treatment wide rang condit includ
migrain diabet psoriasi pancreat cancer kidney diseas critic upcom pipelin event
includ potenti fda approv lasmiditan acut migrain galcanezumab cluster headach
potenti approv ramucirumab second-lin treatment hepatocellular cancer liver phase
data readout drug first-lin treatment lung cancer phase data readout
tanezumab sever pain indic
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care
major develop septemb began process divest anim health
segment estim oper profit initi public offer sold
busi compani divest rest segment exchang offer
complet march june paid billion acquir phase cancer drug
pegilodecakin keep focu grow oncolog portfolio februari acquir
loxo oncolog approxim billion purchas bring pipelin highli select
potenti medicin patient genom defin cancer
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate period adjust pre-tax
incom margin increas mainli due strong perform contain sg
cost remain roughli flat three-year period sale grew materi due
sale growth larg improv profit margin adjust pre-tax incom per share
grew three-year compound-annual-growth-rate compani conserv capit view
ebita-to-interest coverag around
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
outlook sub-industri
next year neutral expect
modest revenu growth driven
slowdown novel drug approv
potenti new price regul
neg partial off-set upcom
favor period patent expir
also expect major gener maker continu
struggl lower cost foreign competit
keep pressur profit margin
banner year new brand
drug fda see slowdown
total novel drug
approv fda
signific surg compar approv
new brand help drive
ebitda growth sub-industri
versu averag
new drug launch appear
slow howev
approv year august
period also observ
yoy declin spend
like portend effort maintain margin
sluggish revenu growth year ahead
pharmaceut also face increas risk
new drug price rule view
accord wall street journal studi
govern health system develop
countri like england norway canada
often pay less major drug
poll indic american feel drug
cost unreason believ
dynam increas pressur drug
maker curtail price hike politician
enact polici lower drug cost
voter accordingli sever new propos
lower drug price emerg side
isl recent month trump
administr announc explor base
medicar drug price intern index
hous democrat introduc bill
would allow medicar directli negoti
price drug maker senat
republican propos lower
out-of-pocket maximum medicar drug
plan shift cost burden
drug maker none propos
current enough support becom law
view see polit parti
increas focu control drug cost
signific risk weigh outlook
sub-industri
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
major gener maker neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
estim india-bas produc oper
averag gross margin
versu top western gener
foreign firm
drop broader composit
year-to-d septemb
pharmaceut index
gain
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
et cfra keep hold opinion share compani
lift target ep
estim -- roughli line histor forward price-to-earnings averag ep
vs line consensu lower ep estim
start sale yoy driven growth
volum partial off-set decreas price neg
currenc impact growth led diabet drug trulic yoy
basaglar yoy well psoriasi drug taltz yoy
robust demand growth three drug account total
sale year ago total revenu growth hinder loss
exclus ciali revenu howev face new gener
competit saw annual sale declin expect gener
revenu growth around rapid growth success newer drug
balanc declin older one without exclus /colin scarola
compani rais target
ep estim line histor averag forward price-to-earnings ep
vs consensu rais ep estim
sale yoy higher volum
partial off-set lower averag price growth led diabet
drug trulic yoy psoriasi drug taltz
yoy robust demand also improv margin quarter
cog sg grow slower revenu combin
effect strong sale growth cost contain estim yoy
increas adj pre-tax incom pipelin encourag fda
approv emgal migrain treatment think
competit sever new migrain drug approv year
june acquisit phase pegilodecakin think promis
orphan drug pancreat cancer /colin scarola
analyst research note compani news
pm et cfra keep hold opinion share compani
lift target ep
estim five-year forward price-to-earnings averag due potenti
price pressur diabet drug gener roughli half revenu
maintain ep estim rais start
forecast sale growth aid fast grow
diabet brand trulic sale yoy growth
basaglar yoy success treat diabet double-edg sword
view think politician increasingli scrutin drug
class due high preval cdc estim live
diabet prediabet recent anecdot evid
illustr scrutini includ decemb report senat elizabeth
warren richard blumenth critic diabet drug market
practic maintain hold rate see sign healthier
sentiment emerg drug portfolio /colin scarola
pm et cfra keep hold opinion share compani
keep target price ep estim
-- roughli line histor forward price-to-earnings averag rais
ep estim leav unchang ep vs
beat consensu saw modest sale growth yoy
growth newer drug mostli balanc lower demand loss
exclus older one good illustr diverg top
two drug trulic sale newer type diabet treatment approv
seen ytd sale grow yoy humalog sale
tradit insulin diabet drug approv saw ytd sale drop much
peer-averag valuat tie trulic growth view
see consider uncertainti outlook drug saw first
sequenti sale declin face intens competit diabet
market share view accordingli remain neutral share /colin
et cfra keep hold opinion share compani
drop target price ep
estim -- roughli line histor forward price-to-earnings averag ep
vs beat consensu rais ep estim
sale grew yoy
drug portfolio current balanc growth newer drug reduc demand
loss exclus older one among top drug perform well
trulic diabet sale grew yoy increas
volum even realiz price declin quarter taltz psoriasi
whose sale jump yoy rise demand strong perform
need off-set yoy declin ciali erectil disfunct due
gener competit yoy drop humalog diabet due lower
price see attract upsid sever big pharma peer
heavili concentr diabet see long-term
pm et cfra keep hold opinion share compani
keep target ep
estim -- roughli line histor forward price-to-earnings averag ep
vs line consensu rais ep estim
keep sale grew yoy driven
growth volum partial off-set drop realiz price
growth led trulic diabet total sale yoy
drug experienc first sequenti sale declin sinc launch
indic us may last year abnorm high
growth face greater competit major drug perform
well humalog diabet yoy tougher competit
alimta sale lung cancer flat due gener entri europ
expect gener ep growth rapid growth
success newer drug balanc declin older one lose exclus
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
compani
